Pathos AI Secures $237M in Series E Funding, Partners with Bristol Myers for Neuroscience

By Priya Anand

Pathos AI, a New York-based biotech company specializing in AI-driven drug development, has announced the completion of a $237 million Series E funding round, achieving a post-money valuation of approximately $3 billion. The financing was led by Bristol Myers Squibb, with participation from existing investors.

The funds will be used to enhance Pathos's AI platform, Foundry, and to advance its oncology pipeline. Key projects include moving JSKN-016, a TROP2/HER3 bispecific ADC, into registrational studies, and progressing other treatments such as pocenbrodib and AZD4241.

In addition to the funding, Pathos has entered into strategic collaborations with Bristol Myers Squibb and Tempus AI to expand into neuroscience drug development. Bristol Myers Squibb gains non-exclusive access to Pathos Foundry and exclusive rights for neuroscience development over three years.

Tempus AI will provide a neurology dataset of 500,000 de-identified patient records over five years, with Pathos committing up to $55 million for this data. The combined agreements with Tempus and Bristol Myers Squibb total $192.5 million over five years.